BELGRADE, Mont., Dec. 08, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly owned subsidiary, X-spine Systems, has received a CE (Conformité Européenne) Mark for the Certex® OCT Spinal Fixation System and is initiating a worldwide launch of the system.
The Certex® OCT Spinal Fixation System complements and completes the CertexTM Cervico-Thoracic Spinal Fixation System. The Certex® System is intended to promote fusion of the occipito-cervico-thoracic regions of the spine (Occiput-T3 inclusive).
“The Certex® OCT was developed with a panel of designing surgeons to address market and patient needs worldwide. It is Xtant Medical’s mission to lead through innovative design with surgeon practicality” stated Greg Causey, Ph.D, Vice President of Engineering at Xtant Medical.
According to the 2015 iData report, the total addressable US market for posterior cervical fixation with an occipitocervical plate is $299M and growing.
About Xtant Medical Holdings
Xtant Medical Holdings, Inc. (NYSE:XTNT) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For further information, please visit www.xtantmedical.com.
Important Cautions Regarding Forward-looking Statements
This press release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability to successfully integrate the acquisition of X-spine; the ability of the Company's sales force to achieve expected results; the Company's ability to meet its existing and anticipated contractual obligations, including financial covenant and other obligations contained in the Company's secured lending facility; the Company's ability to manage cash flow; the Company's ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company's customers to pay and the timeliness of such payments; the Company's ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills and expertise; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.
COCKRELL GROUP 877.889.1972 [email protected] cockrellgroup.com


Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 



